Funding Opportunity RFA-RM-18-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications proposing research on the development of novel and optimized alternatives to existing in vivo genome editing complexes.

Funding Opportunity RFA-RM-18-023 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating the development of genome editing therapeutics to treat human disease.

Funding Opportunity RFA-RM-18-022 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate cell- and tissue-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.

Funding Opportunity PA-18-876 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics, Genomics, Central London - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Geno City of London, England

Funding Opportunity PA-18-874 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/ developmental research on biologic factors that mediate the differences in prevalence and severity of Dental, Oral, and Craniofacial (DOC)-related diseases and conditions in oral health disparities populations. It is long recognized that certain racial and ethnic populations suffer an increased burden of DOC diseases and conditions, such as oral/oropharyngeal cancers, early childhood caries (ECC), dental caries, and periodontitis. For each of these diseases, substantial racial and ethnic differences exist in prevalence, severity, persistence and/or disease progression. Biologic factors are believed to play a role in oral health disparities in addition to behavioral, social, and environmental factors. Because critical scientific gaps remain in our understanding of underlying biologic mechanisms that could contribute to these differences, it is difficult to develop targeted therapeutic regimens for those in greatest need.

Funding Opportunity PAR-18-875 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.

Notice NOT-CA-18-096 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-019 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-079 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-18-873 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

Funding Opportunity PA-18-872 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

Funding Opportunity PA-18-871 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research.

Funding Opportunity PA-18-870 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

Funding Opportunity RFA-AI-18-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

Funding Opportunity PAR-18-869 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Negotiable: Paramount Recruitment: Cancer Bioinformatician 100,000 Genomes Project - Bioinformatics - Central London! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Funding Opportunity PAR-18-866 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.

Funding Opportunity RFA-AR-19-012 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.

Funding Opportunity PA-18-867 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification as variants of uncertain significance (VUS), which makes clinical implementation difficult. This Program Announcement and the companion R21 Program Announcement aim to support the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically.